Homoharringtonine Synergy with Oridonin in Treatment of T(8; 21) Acute Myeloid Leukemia

Overview

Journal Front Med

Specialty General Medicine

Date 2018 Sep 13

PMID 30206768

Citations 13

Authors

Weina Zhang

Ying Lu

Tao Zhen

Xinjie Chen

Ming Zhang

Ping Liu

Xiangqin Weng

Bing Chen

Yueying Wang

Affiliations

Soon will be listed here.

Abstract

Collaboration of c-KIT mutations with AML1-ETO (AE) has been demonstrated to induce t(8; 21) acute myeloid leukemia (AML). Targeted therapies designed to eliminate AE and c-KIT oncoproteins may facilitate effective treatment of t(8; 21) AML. Homoharringtonine (HHT) features activity against tumor cells harboring c-KIT mutations, whereas oridonin can induce t(8; 21) AML cell apoptosis and AE cleavage. Therefore, studies should explore the efficacy of combination therapy with oridonin and HHT in t(8; 21) AML. In this study, we investigated the synergistic effects and mechanism of oridonin combined with HHT in t(8; 21) AML cell line and mouse model. The two drugs synergistically inhibited cell viability and induced significant mitochondrial membrane potential loss and apoptosis. Oridonin and HHT induced significant downregulation of c-KIT and its downstream signaling pathways and promoted AE cleavage. HHT increased intracellular oridonin concentration by modulating the expressions of MRP1 and MDR1, thus enhancing the effects of oridonin. The combination of oridonin and HHT prolonged t(8; 21) leukemia mouse survival. In conclusion, oridonin and HHTexert synergistic effects against t(8; 21) leukemia in vivo and in vitro, thereby indicating that their combination may be an effective therapy for t(8; 21) leukemia.

Citing Articles

Homoharringtonine: mechanisms, clinical applications and research progress.

Wang W, He L, Lin T, Xiang F, Wu Y, Zhou F Front Oncol. 2025; 15:1522273.

PMID: 39949739 PMC: 11821653. DOI: 10.3389/fonc.2025.1522273.

Therapeutic Potential of Terpenoids in Cancer Treatment: Targeting Mitochondrial Pathways.

Guo J, Huang M, Hou S, Yuan J, Chang X, Gao S Cancer Rep (Hoboken). 2024; 7(9):e70006.

PMID: 39234662 PMC: 11375335. DOI: 10.1002/cnr2.70006.

Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications.

Khatua S, Nandi S, Nag A, Sen S, Chakraborty N, Naskar A Eur J Med Res. 2024; 29(1):269.

PMID: 38704602 PMC: 11069164. DOI: 10.1186/s40001-024-01856-x.

Homoharringtonine promotes heart allograft acceptance by enhancing regulatory T cells induction in a mouse model.

Qiu X, Zhang H, Tang Z, Fan Y, Yuan W, Feng C Chin Med J (Engl). 2023; 137(12):1453-1464.

PMID: 37962205 PMC: 11188914. DOI: 10.1097/CM9.0000000000002813.

Recent advances in oridonin derivatives with anticancer activity.

Sobral P, Vicente A, Salvador J Front Chem. 2023; 11:1066280.

PMID: 36846854 PMC: 9947293. DOI: 10.3389/fchem.2023.1066280.

References

Kantarjian H, Talpaz M, Santini V, Murgo A, Cheson B, OBrien S . Homoharringtonine: history, current research, and future direction. Cancer. 2001; 92(6):1591-605. DOI: 10.1002/1097-0142(20010915)92:6<1591::aid-cncr1485>3.0.co;2-u. View

Kelly L, Gilliland D . Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002; 3:179-98. DOI: 10.1146/annurev.genom.3.032802.115046. View

Wang Y, Zhou G, Yin T, Chen B, Shi J, Liang W . AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A. 2005; 102(4):1104-9. PMC: 545849. DOI: 10.1073/pnas.0408831102. View

Lennartsson J, Ronnstrand L . The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets. 2006; 6(1):65-75. DOI: 10.2174/156800906775471725. View

Tang R, Faussat A, Majdak P, Marzac C, Dubrulle S, Marjanovic Z . Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006; 5(3):723-31. DOI: 10.1158/1535-7163.MCT-05-0164. View

Chou T . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-81. DOI: 10.1124/pr.58.3.10. View

Zhou G, Kang H, Wang L, Gao L, Liu P, Xie J . Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood. 2007; 109(8):3441-50. PMC: 1852250. DOI: 10.1182/blood-2006-06-032250. View

Jiao B, Wu C, Liang Y, Chen H, Xiong S, Chen B . AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia. 2009; 23(9):1598-604. DOI: 10.1038/leu.2009.104. View

Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, Zhu F . The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther. 2010; 9(1):211-23. DOI: 10.1158/1535-7163.MCT-09-0468. View

10.

Fletcher J, Haber M, Henderson M, Norris M . ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010; 10(2):147-56. DOI: 10.1038/nrc2789. View

11.

Chen R, Guo L, Chen Y, Jiang Y, Wierda W, Plunkett W . Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2010; 117(1):156-64. PMC: 3037741. DOI: 10.1182/blood-2010-01-262808. View

12.

Wang Y, Zhao L, Wu C, Liu P, Shi L, Liang Y . C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A. 2011; 108(6):2450-5. PMC: 3038718. DOI: 10.1073/pnas.1019625108. View

13.

Allan E, Holyoake T, Craig A, Jorgensen H . Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia. 2011; 25(6):985-94. DOI: 10.1038/leu.2011.55. View

14.

Zhen T, Wu C, Liu P, Wu H, Zhou G, Lu Y . Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med. 2012; 4(127):127ra38. DOI: 10.1126/scitranslmed.3003562. View

15.

Koley D, Bard A . Inhibition of the MRP1-mediated transport of the menadione-glutathione conjugate (thiodione) in HeLa cells as studied by SECM. Proc Natl Acad Sci U S A. 2012; 109(29):11522-7. PMC: 3406878. DOI: 10.1073/pnas.1201555109. View

16.

Obuchi W, Ohtsuki S, Uchida Y, Ohmine K, Yamori T, Terasaki T . Identification of transporters associated with Etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics. Mol Pharmacol. 2012; 83(2):490-500. DOI: 10.1124/mol.112.081083. View

17.

Jin J, Wang J, Chen F, Wu D, Hu J, Zhou J . Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013; 14(7):599-608. DOI: 10.1016/S1470-2045(13)70152-9. View

18.

Stankov K, Popovic S, Mikov M . C-KIT signaling in cancer treatment. Curr Pharm Des. 2013; 20(17):2849-80. DOI: 10.2174/13816128113199990593. View

19.

Alvandi F, Kwitkowski V, Ko C, Rothmann M, Ricci S, Saber H . U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist. 2013; 19(1):94-9. PMC: 3903068. DOI: 10.1634/theoncologist.2013-0077. View

20.

Zhu H, Jiang H, Jiang Q, Jia J, Qin Y, Huang X . Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21). Leuk Res. 2016; 44:40-4. DOI: 10.1016/j.leukres.2016.02.012. View